5 Best Stocks to Buy for Short Term

2. Corcept Therapeutics Incorporated (NASDAQ:CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORT) is among the 5 Best Stocks to Buy for Short Term. On March 25, Wolfe Research upgraded Corcept Therapeutics Incorporated (NASDAQ:CORT) to Peerperform from Underperform following the FDA approval for relacorilant. The firm believes this approval will remove a major downside risk for the stock, adding that the sustainability of the company’s core Cushing’s syndrome franchise remains unclear.

On the same day, Corcept Therapeutics Incorporated (NASDAQ:CORT) announced that the U.S. Food and Drug Administration approved Lifyorli (relacorilant) in combination with nab-paclitaxel as a solution for patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. This drug marks the first FDA-approved selective glucocorticoid receptor antagonist.

The trial achieved its dual primary endpoints, with patients treated with Lifyorli plus nab-paclitaxel witnessing a 35% reduction in the risk of death relative to patients treated with nab-paclitaxel alone. Additionally, patients saw a 30% lower risk of disease progression.

Overall, Corcept Therapeutics Incorporated (NASDAQ:CORT) has a Buy rating from 71% of the analysts covering the stock, with the remaining 29% holding a cautious view. The 1-year median price target of $60 reflects an upside potential of 59.19%.

Corcept Therapeutics Incorporated (NASDAQ:CORT), incorporated in 1998, is a California-based biopharmaceutical company that discovers and develops solutions for serious endocrinologic, oncologic, metabolic, and neurologic disorders.